Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the safety and efficacy (how well it works) of
exenatide as a treatment for weight gain associated with olanzapine in obese adults with
Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder
Exenatide has been approved by the FDA for the treatment of Type 2 diabetes.
It has not been approved for the treatment of weight gain associated with olanzapine in obese
adults with bipolar disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective
Disorder